CRISCITIELLO, CARMEN
CRISCITIELLO, CARMEN
Dipartimento di Oncologia ed Emato-Oncologia
Overcoming Resistance to CDK4/6 inhibitors in Hormone Receptor positive, HER2 negative breast cancer: Innovative Combinations and Emerging Strategies
2025 F. Giugliano, C. De Angelis, B. Pistilli, G. Viale, G. Bianchini, M. Giuliano, L. Malorni, B. Taurelli Salimbeni, A. Esposito, A. Giordano, T.A. Yap, G. Curigliano, C. Criscitiello
Molecular tumor board in patients with metastatic breast cancer
2025 L. Boscolo Bielo, E. Guerini Rocco, E. Crimini, M. Repetto, M. Lombardi, C. Zanzottera, G. Aurilio, M. Barberis, C. Belli, Y. Zhan, E. Battaiotto, J. Katrini, R. Marsicano, P. Zagami, B. Taurelli Salimbeni, A. Esposito, D. Trapani, C. Criscitiello, N. Fusco, A. Marra, G. Curigliano
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy
2025 C. Corti, B. Binboğa Kurt, B. Koca, T. Rahman, F. Conforti, L. Pala, G. Bianchini, C. Criscitiello, G. Curigliano, A.C. Garrido-Castro, S.K. Kabraji, A.G. Waks, E.A. Mittendorf, S.M. Tolaney
Mismatch repair (MMR) and microsatellite instability (MSI) phenotypes across solid tumors: A comprehensive cBioPortal study on prevalence and prognostic impact
2025 K. Venetis, C. Frascarelli, L.B. Bielo, G. Cursano, R. Adorisio, M. Ivanova, E. Mane, V. Peruzzo, A. Concardi, M. Negrelli, M. D'Ercole, F.M. Porta, Y. Zhan, A. Marra, D. Trapani, C. Criscitiello, G. Curigliano, E. Guerini-Rocco, N. Fusco
Oral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences
2025 R. Scafetta, P. Zagami, M. Del Re, C. Criscitiello, A. Marra, G. Curigliano
Radioligand Therapy in Metastatic Breast Cancer: Harnessing Precision Oncology
2025 F. Giugliano, E. Giordano, L. Gilardi, B.T. Salimbeni, P. Zagami, A. Esposito, A. Marra, D. Trapani, P.P.M. Berton Giachetti, B. Malagutti, T. Henry, D. Deandreis, G. Curigliano, F. Ceci, C. Criscitiello
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
2025 P. Zagami, A. Esposito, B. Taurelli Salimbeni, P.P.M. Berton Giachetti, R. Scafetta, M. Lambertini, M. Di Maio, G. Curigliano, C. Criscitiello, S. Cinieri
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer
2025 R. Bartsch, D. Cameron, E. Ciruelos, C. Criscitiello, G. Curigliano, F.P. Duhoux, T. Foukakis, J. Gligorov, N. Harbeck, N. Levasseur, A. Okines, F. Penault-Llorca, V. Müller
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
2025 B. Taurelli Salimbeni, F. Giudici, C. Pescia, P.P.M. Berton Giachetti, R. Scafetta, P. Zagami, A. Marra, D. Trapani, A. Esposito, S. Scagnoli, B. Cerbelli, A. Botticelli, E. Munzone, N. Fusco, C. Criscitiello, G. Curigliano
Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group
2025 G. Corso, S. Shen, C. Criscitiello, R. Mukhtar, L. Gamble, E.G. Rocco, F. Pesapane, L. Nicosia, K. Jhaveri, B.T. Salimbeni, G. Massari, E. Meduri, A.M. De Scalzi, A. Concardi, F. Magnoni, A. Mamtani, F. Pareja, M.C. Leonardi, V. Sacchini, G. Bogani, C.L. Vecchia, D. Presti, M.A. Colleoni, P. Veronesi, M.E. Robson
Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer
2025 G. Cursano, A. Concardi, M. Ivanova, C. Frascarelli, E. Mane, E. Mangione, S. Santaguida, D. Tosoni, S. Pece, A. Marra, C. Criscitiello, G. Curigliano, G. Viale, K. Venetis, E.G. Rocco, N. Fusco
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
2025 K. Venetis, G. Cursano, R. Scafetta, P.P.M.B. Giachetti, A. Concardi, E. De Camilli, M. D'Ercole, E. Mane, C. Frascarelli, A. Marra, S. Gandini, F. Pepe, S. Scagnoli, S.M. Rossi, R. Troiano, E. Speziale, C. De Angelis, G. Troncone, U. Malapelle, G. Perrone, A. Botticelli, G. Viale, G. Curigliano, E. Guerini Rocco, C. Criscitiello, N. Fusco
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer
2025 M. Milano, C. Valenza, A. Ferrari, S. Gandini, D. Trapani, C. Santoro, E. Battaiotto, A. Carnevale Schianca, E. Giordano, J. Katrini, G. Castellano, B. Taurelli Salimbeni, M.C. Leonardi, S. Dicuonzo, C. Criscitiello, N. Bianco, S. Dellapasqua, E. Munzone, G. Curigliano, M. Colleoni, B.A. Jereczek-Fossa
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
2025 P.P.M. Berton Giachetti, S. Morganti, S. Gandini, F. Giudici, A. Marra, E. Nicolò, E. Zattarin, C. Corti, L. Boldrini, A. Verrazzo, C. Sposetti, M.G. Razeti, A. Carnevale Schianca, R. Scafetta, B. Taurelli Salimbeni, A. Esposito, P. Zagami, D. Trapani, B. Malagutti, R. Caputo, C. Vernieri, E. Munzone, S. Scagnoli, A. Botticelli, M. Lambertini, M. Giuliano, M. De Laurentiis, G. Viale, G. Bianchini, G. Curigliano, C. De Angelis, C. Criscitiello
Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status
2025 M. Lambertini, E. Blondeaux, L.M. Tomasello, E. Agostinetto, A. Hamy, H.J. Kim, M.A. Franzoi, R. Bernstein-Molho, F. Hilbers, K. Pogoda, H. Wildiers, J. Bajpai, M. Ignatiadis, H.C.F. Moore, A.H. Partridge, K. Phillips, A. Toss, C. Rousset-Jablonski, C. Criscitiello, T. Renaud, A. Ferrari, S. Paluch-Shimon, R. Fruscio, W. Cui, S.M. Wong, C. Vernieri, K.J. Ruddy, M.V. Dieci, A. Matikas, M. Rozenblit, C. Villarreal-Garza, L. De Marchis, F. Puglisi, K.A. Rodriguez-Wallberg, F.P. Duhoux, L. Livraghi, M. Bruzzone, L. Boni, J. Balmaña
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study
2024 C. Valenza, D. Trapani, P. Zagami, G. Antonarelli, L. Boscolo Bielo, E. Nicolò, J.M. Ribeiro, L. Guidi, C. Reduzzi, M. Spotti, L. Adamoli, J. Cortès, B. Pistilli, S.M. Tolaney, N. Ueno, R.M. Layman, M. Cristofanilli, L.A. Carey, E. Munzone, C. Criscitiello, F. Lynce, W.A. Woodward, G. Curigliano
Effect of age on safety and efficacy of novel cancer drugs investigated in early-phase clinical trials
2024 E. Nicolò, S. Gandini, F. Giugliano, J. Uliano, O. D'Ecclesiis, S. Morganti, E. Ferraro, D. Trapani, P. Tarantino, P. Zagami, L. Boldrini, I. Caramella, A. Carnevale Schianca, M. Cristofanilli, M.A. Locatelli, A. Esposito, C. Belli, I. Minchella, C. Criscitiello, A. Marra, G. Curigliano
The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer
2024 L. Boscolo Bielo, D. Trapani, E. Nicolò, C. Valenza, L. Guidi, C. Belli, E. Kotteas, A. Marra, A. Prat, N. Fusco, C. Criscitiello, H.J. Burstein, G. Curigliano
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer
2024 R.A. Leon-Ferre, S.F. Jonas, R. Salgado, S. Loi, V. De Jong, J.M. Carter, T.O. Nielsen, S. Leung, N. Riaz, S. Chia, G. Jules-Clément, G. Curigliano, C. Criscitiello, V. Cockenpot, M. Lambertini, V.J. Suman, B. Linderholm, J.W.M. Martens, C.H.M. Van Deurzen, A.M. Timmermans, T. Shimoi, S. Yazaki, M. Yoshida, S. Kim, H.J. Lee, M.V. Dieci, G. Bataillon, A. Vincent-Salomon, F. André, M. Kok, S.C. Linn, M.P. Goetz, S. Michiels, N. Null
Immune-Related Adverse Event Likelihood Score Identifies “Pure” IRAEs Strongly Associated With Outcome in a Phase I-II Trial Population
2024 L. Mazzarella, F. Giugliano, E. Nicolo, A. Esposito, E. Crimini, G. Tini, J. Uliano, C. Corti, P. D'Amico, P.T. Aliaga, C. Valenza, M. Repetto, G. Antonarelli, L. Ascione, G. Vivanet, P.P.M. Berton Giachetti, I. Minchella, C. Belli, M. Locatelli, C. Criscitiello, G. Curigliano